JP2010506856A5 - - Google Patents

Info

Publication number

JP2010506856A5

JP2010506856A5 JP2009532619A JP2009532619A JP2010506856A5 JP 2010506856 A5 JP2010506856 A5 JP 2010506856A5 JP 2009532619 A JP2009532619 A JP 2009532619A JP 2009532619 A JP2009532619 A JP 2009532619A JP 2010506856 A5 JP2010506856 A5 JP 2010506856A5

Authority

JP

Japan

Prior art keywords

arh

meoh

mmol

amino

acid

Prior art date

2007-10-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 807
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 313
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 258
• 150000001875 compounds Chemical class 0.000 description 161
• 235000019439 ethyl acetate Nutrition 0.000 description 155
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 140
• 239000000203 mixture Substances 0.000 description 125
• 238000005481 NMR spectroscopy Methods 0.000 description 109
• 238000010992 reflux Methods 0.000 description 98
• 239000011541 reaction mixture Substances 0.000 description 91
• 239000000243 solution Substances 0.000 description 89
• 239000007787 solid Substances 0.000 description 80
• 206010028980 Neoplasm Diseases 0.000 description 76
• 238000000034 method Methods 0.000 description 73
• 230000002829 reductive effect Effects 0.000 description 69
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 66
• 239000002904 solvent Substances 0.000 description 65
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 64
• 210000004027 cell Anatomy 0.000 description 64
• 239000000725 suspension Substances 0.000 description 64
• 150000003839 salts Chemical class 0.000 description 62
• 235000002639 sodium chloride Nutrition 0.000 description 62
• 239000008194 pharmaceutical composition Substances 0.000 description 61
• 239000002244 precipitate Substances 0.000 description 60
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 56
• -1 quinoline derivative compounds Chemical class 0.000 description 56
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 55
• 201000010099 disease Diseases 0.000 description 51
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 50
• 150000001412 amines Chemical class 0.000 description 49
• 230000000694 effects Effects 0.000 description 48
• 239000000843 powder Substances 0.000 description 45
• 108020004414 DNA Proteins 0.000 description 44
• 229910052739 hydrogen Inorganic materials 0.000 description 44
• 230000007067 DNA methylation Effects 0.000 description 43
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 42
• 229940002612 prodrug Drugs 0.000 description 41
• 239000000651 prodrug Substances 0.000 description 41
• 108090000623 proteins and genes Proteins 0.000 description 40
• 201000011510 cancer Diseases 0.000 description 38
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 36
• 238000002360 preparation method Methods 0.000 description 32
• KNDOFJFSHZCKGT-UHFFFAOYSA-N 4-chloroquinoline Chemical compound C1=CC=C2C(Cl)=CC=NC2=C1 KNDOFJFSHZCKGT-UHFFFAOYSA-N 0.000 description 31
• 108010057281 Lipocalin 1 Proteins 0.000 description 31
• 102100034724 Lipocalin-1 Human genes 0.000 description 31
• 238000004809 thin layer chromatography Methods 0.000 description 31
• 239000003814 drug Substances 0.000 description 28
• 230000002159 abnormal effect Effects 0.000 description 27
• 239000003112 inhibitor Substances 0.000 description 27
• 229910052757 nitrogen Inorganic materials 0.000 description 27
• SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 26
• 239000002253 acid Substances 0.000 description 26
• 102000003964 Histone deacetylase Human genes 0.000 description 25
• 108090000353 Histone deacetylase Proteins 0.000 description 25
• 238000002844 melting Methods 0.000 description 25
• 230000008018 melting Effects 0.000 description 25
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 24
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
• 230000015572 biosynthetic process Effects 0.000 description 24
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 23
• 238000009472 formulation Methods 0.000 description 23
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 22
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 22
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 21
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
• 238000004128 high performance liquid chromatography Methods 0.000 description 21
• 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 20
• 229960003603 decitabine Drugs 0.000 description 20
• 230000011987 methylation Effects 0.000 description 20
• 238000007069 methylation reaction Methods 0.000 description 20
• 150000001408 amides Chemical class 0.000 description 19
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 19
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 19
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 18
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 18
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 18
• 239000003054 catalyst Substances 0.000 description 18
• ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 17
• FLKFKUSJAFUYDU-UHFFFAOYSA-N 4-chloro-6-nitroquinoline Chemical compound N1=CC=C(Cl)C2=CC([N+](=O)[O-])=CC=C21 FLKFKUSJAFUYDU-UHFFFAOYSA-N 0.000 description 17
• 229910052799 carbon Inorganic materials 0.000 description 17
• 239000003795 chemical substances by application Substances 0.000 description 17
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 17
• NPTGVVKPLWFPPX-UHFFFAOYSA-N 2-amino-4-chloro-6-methylpyrimidine Chemical compound CC1=CC(Cl)=NC(N)=N1 NPTGVVKPLWFPPX-UHFFFAOYSA-N 0.000 description 16
• 230000033115 angiogenesis Effects 0.000 description 16
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
• 229940124597 therapeutic agent Drugs 0.000 description 16
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 16
• 229940093475 2-ethoxyethanol Drugs 0.000 description 15
• 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 15
• 230000002401 inhibitory effect Effects 0.000 description 15
• 239000000047 product Substances 0.000 description 15
• 108010033040 Histones Proteins 0.000 description 14
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 14
• 238000006243 chemical reaction Methods 0.000 description 14
• 239000000706 filtrate Substances 0.000 description 14
• 238000004949 mass spectrometry Methods 0.000 description 13
• VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 13
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 12
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 12
• WWSKGXHXNSJFDH-UHFFFAOYSA-N 4-chloro-n,n-dimethylquinolin-6-amine Chemical compound N1=CC=C(Cl)C2=CC(N(C)C)=CC=C21 WWSKGXHXNSJFDH-UHFFFAOYSA-N 0.000 description 12
• RSILXKGPRQLNLJ-UHFFFAOYSA-N 4-chloro-n,n-dimethylquinolin-7-amine Chemical compound ClC1=CC=NC2=CC(N(C)C)=CC=C21 RSILXKGPRQLNLJ-UHFFFAOYSA-N 0.000 description 12
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 12
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
• 229960000583 acetic acid Drugs 0.000 description 12
• 238000004458 analytical method Methods 0.000 description 12
• 239000002246 antineoplastic agent Substances 0.000 description 12
• 230000001684 chronic effect Effects 0.000 description 12
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
• 125000000753 cycloalkyl group Chemical group 0.000 description 12
• 210000001519 tissue Anatomy 0.000 description 12
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 11
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 11
• 229940079593 drug Drugs 0.000 description 11
• 230000014509 gene expression Effects 0.000 description 11
• 238000002953 preparative HPLC Methods 0.000 description 11
• 238000003786 synthesis reaction Methods 0.000 description 11
• UPZGWWDLHRREJM-UHFFFAOYSA-N 4-chloro-7-nitroquinoline Chemical compound ClC1=CC=NC2=CC([N+](=O)[O-])=CC=C21 UPZGWWDLHRREJM-UHFFFAOYSA-N 0.000 description 10
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• 208000005890 Neuroma Diseases 0.000 description 10
• 206010039491 Sarcoma Diseases 0.000 description 10
• 229940088598 enzyme Drugs 0.000 description 10
• SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical group [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 description 10
• 206010020718 hyperplasia Diseases 0.000 description 10
• NRTUTGBOQZQBMB-UHFFFAOYSA-N n-phenylquinolin-4-amine Chemical class C=1C=NC2=CC=CC=C2C=1NC1=CC=CC=C1 NRTUTGBOQZQBMB-UHFFFAOYSA-N 0.000 description 10
• 229910052763 palladium Inorganic materials 0.000 description 10
• 238000000746 purification Methods 0.000 description 10
• 230000035897 transcription Effects 0.000 description 10
• 238000013518 transcription Methods 0.000 description 10
• XGAFCCUNHIMIRV-UHFFFAOYSA-N 4-chloropyridine;hydron;chloride Chemical group Cl.ClC1=CC=NC=C1 XGAFCCUNHIMIRV-UHFFFAOYSA-N 0.000 description 9
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 9
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 9
• 108090000695 Cytokines Proteins 0.000 description 9
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
• 108060004795 Methyltransferase Proteins 0.000 description 9
• 102000016397 Methyltransferase Human genes 0.000 description 9
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 9
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 9
• 208000025865 Ulcer Diseases 0.000 description 9
• 235000011054 acetic acid Nutrition 0.000 description 9
• 125000000217 alkyl group Chemical group 0.000 description 9
• 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 9
• 235000019441 ethanol Nutrition 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 208000020816 lung neoplasm Diseases 0.000 description 9
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 8
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
• 208000003174 Brain Neoplasms Diseases 0.000 description 8
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
• 206010018691 Granuloma Diseases 0.000 description 8
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
• 108091000080 Phosphotransferase Proteins 0.000 description 8
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
• 201000000582 Retinoblastoma Diseases 0.000 description 8
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 8
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 8
• 230000001594 aberrant effect Effects 0.000 description 8
• 239000002168 alkylating agent Substances 0.000 description 8
• 229940100198 alkylating agent Drugs 0.000 description 8
• 235000001014 amino acid Nutrition 0.000 description 8
• 229940024606 amino acid Drugs 0.000 description 8
• 208000037976 chronic inflammation Diseases 0.000 description 8
• 150000004985 diamines Chemical class 0.000 description 8
• 229910052736 halogen Inorganic materials 0.000 description 8
• 150000002367 halogens Chemical class 0.000 description 8
• 208000014951 hematologic disease Diseases 0.000 description 8
• 238000005342 ion exchange Methods 0.000 description 8
• 208000032839 leukemia Diseases 0.000 description 8
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
• 201000008968 osteosarcoma Diseases 0.000 description 8
• 229910052760 oxygen Inorganic materials 0.000 description 8
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 8
• 102000020233 phosphotransferase Human genes 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
• 201000000849 skin cancer Diseases 0.000 description 8
• 206010041823 squamous cell carcinoma Diseases 0.000 description 8
• NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 7
• PXSLJSOKYINMSP-UHFFFAOYSA-N 3-amino-n-(4-nitrophenyl)benzamide Chemical compound NC1=CC=CC(C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)=C1 PXSLJSOKYINMSP-UHFFFAOYSA-N 0.000 description 7
• OYCOCVPHRYOCBU-UHFFFAOYSA-N 4-n-(4-aminophenyl)-6-n,6-n-dimethylquinoline-4,6-diamine Chemical compound C12=CC(N(C)C)=CC=C2N=CC=C1NC1=CC=C(N)C=C1 OYCOCVPHRYOCBU-UHFFFAOYSA-N 0.000 description 7
• TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 7
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 7
• 206010006187 Breast cancer Diseases 0.000 description 7
• 208000026310 Breast neoplasm Diseases 0.000 description 7
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 7
• 206010009944 Colon cancer Diseases 0.000 description 7
• 229920000858 Cyclodextrin Polymers 0.000 description 7
• 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 7
• 241000196324 Embryophyta Species 0.000 description 7
• 102000006947 Histones Human genes 0.000 description 7
• 208000000453 Skin Neoplasms Diseases 0.000 description 7
• 229940034982 antineoplastic agent Drugs 0.000 description 7
• 229960002756 azacitidine Drugs 0.000 description 7
• 239000012267 brine Substances 0.000 description 7
• 239000003610 charcoal Substances 0.000 description 7
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 7
• 239000003937 drug carrier Substances 0.000 description 7
• 238000010438 heat treatment Methods 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 230000003211 malignant effect Effects 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
• ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 6
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 6
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
• 102000014150 Interferons Human genes 0.000 description 6
• 108010050904 Interferons Proteins 0.000 description 6
• 102000015696 Interleukins Human genes 0.000 description 6
• 108010063738 Interleukins Proteins 0.000 description 6
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 6
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
• 208000024770 Thyroid neoplasm Diseases 0.000 description 6
• 150000001413 amino acids Chemical class 0.000 description 6
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
• 238000009835 boiling Methods 0.000 description 6
• 208000029742 colonic neoplasm Diseases 0.000 description 6
• 239000012043 crude product Substances 0.000 description 6
• 150000002148 esters Chemical class 0.000 description 6
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
• 238000001914 filtration Methods 0.000 description 6
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 239000002955 immunomodulating agent Substances 0.000 description 6
• 229940121354 immunomodulator Drugs 0.000 description 6
• 238000010348 incorporation Methods 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 238000001802 infusion Methods 0.000 description 6
• 230000003834 intracellular effect Effects 0.000 description 6
• TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 6
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
• 238000001819 mass spectrum Methods 0.000 description 6
• 206010061289 metastatic neoplasm Diseases 0.000 description 6
• 238000012544 monitoring process Methods 0.000 description 6
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 6
• 150000004492 retinoid derivatives Chemical class 0.000 description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 description 6
• 208000007056 sickle cell anemia Diseases 0.000 description 6
• 201000002510 thyroid cancer Diseases 0.000 description 6
• 230000000699 topical effect Effects 0.000 description 6
• RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 6
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 5
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 5
• 208000003200 Adenoma Diseases 0.000 description 5
• 208000018084 Bone neoplasm Diseases 0.000 description 5
• 201000009030 Carcinoma Diseases 0.000 description 5
• 102000003951 Erythropoietin Human genes 0.000 description 5
• 108090000394 Erythropoietin Proteins 0.000 description 5
• 208000007766 Kaposi sarcoma Diseases 0.000 description 5
• 208000008839 Kidney Neoplasms Diseases 0.000 description 5
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
• 206010025323 Lymphomas Diseases 0.000 description 5
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
• 108090000028 Neprilysin Proteins 0.000 description 5
• 102000003729 Neprilysin Human genes 0.000 description 5
• 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 5
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 description 5
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 description 5
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 5
• 206010060862 Prostate cancer Diseases 0.000 description 5
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
• 206010038389 Renal cancer Diseases 0.000 description 5
• 229910004298 SiO 2 Inorganic materials 0.000 description 5
• RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 5
• 102100033254 Tumor suppressor ARF Human genes 0.000 description 5
• 108091008605 VEGF receptors Proteins 0.000 description 5
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 210000000577 adipose tissue Anatomy 0.000 description 5
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
• 239000002585 base Substances 0.000 description 5
• 239000003124 biologic agent Substances 0.000 description 5
• 210000000601 blood cell Anatomy 0.000 description 5
• 210000004204 blood vessel Anatomy 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
• 150000003841 chloride salts Chemical class 0.000 description 5
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 5
• 230000008878 coupling Effects 0.000 description 5
• 238000010168 coupling process Methods 0.000 description 5
• 238000005859 coupling reaction Methods 0.000 description 5
• 238000000354 decomposition reaction Methods 0.000 description 5
• 238000010828 elution Methods 0.000 description 5
• 229940105423 erythropoietin Drugs 0.000 description 5
• 239000000469 ethanolic extract Substances 0.000 description 5
• 239000000284 extract Substances 0.000 description 5
• 230000030279 gene silencing Effects 0.000 description 5
• 239000003292 glue Substances 0.000 description 5
• 229940088597 hormone Drugs 0.000 description 5
• 239000005556 hormone Substances 0.000 description 5
• 210000004969 inflammatory cell Anatomy 0.000 description 5
• 201000010982 kidney cancer Diseases 0.000 description 5
• 201000005202 lung cancer Diseases 0.000 description 5
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
• 201000001441 melanoma Diseases 0.000 description 5
• 230000001394 metastastic effect Effects 0.000 description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
• 201000000050 myeloid neoplasm Diseases 0.000 description 5
• 201000002528 pancreatic cancer Diseases 0.000 description 5
• 208000008443 pancreatic carcinoma Diseases 0.000 description 5
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 5
• 206010040882 skin lesion Diseases 0.000 description 5
• 231100000444 skin lesion Toxicity 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• 230000002792 vascular Effects 0.000 description 5
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 5
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 5
• 229960000237 vorinostat Drugs 0.000 description 5
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 4
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
• IBAHBZYXWUXTLE-UHFFFAOYSA-N 3-[(2-amino-6-methylpyrimidin-3-ium-4-yl)amino]-n-[4-[[6-(dimethylamino)quinolin-4-yl]amino]phenyl]benzamide;chloride Chemical compound [Cl-].C12=CC(N(C)C)=CC=C2[NH+]=CC=C1NC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1NC1=CC(C)=NC(N)=N1 IBAHBZYXWUXTLE-UHFFFAOYSA-N 0.000 description 4
• DTFQMPQJMDEWKJ-UHFFFAOYSA-N 3-ethoxybenzoic acid Chemical compound CCOC1=CC=CC(C(O)=O)=C1 DTFQMPQJMDEWKJ-UHFFFAOYSA-N 0.000 description 4
• XJCVRTZCHMZPBD-UHFFFAOYSA-N 3-nitroaniline Chemical compound NC1=CC=CC([N+]([O-])=O)=C1 XJCVRTZCHMZPBD-UHFFFAOYSA-N 0.000 description 4
• OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 4
• GEIZYPUHEGXPEQ-UHFFFAOYSA-M 4-pyridin-1-ium-1-ylpyridine;chloride Chemical compound [Cl-].C1=CC=CC=[N+]1C1=CC=NC=C1 GEIZYPUHEGXPEQ-UHFFFAOYSA-M 0.000 description 4
• 102100032187 Androgen receptor Human genes 0.000 description 4
• 206010004146 Basal cell carcinoma Diseases 0.000 description 4
• 206010005949 Bone cancer Diseases 0.000 description 4
• 102100024154 Cadherin-13 Human genes 0.000 description 4
• 102100026548 Caspase-8 Human genes 0.000 description 4
• 206010008263 Cervical dysplasia Diseases 0.000 description 4
• 208000031404 Chromosome Aberrations Diseases 0.000 description 4
• 208000011231 Crohn disease Diseases 0.000 description 4
• 102100024462 Cyclin-dependent kinase 4 inhibitor B Human genes 0.000 description 4
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• 208000006168 Ewing Sarcoma Diseases 0.000 description 4
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 4
• 102100037156 Gap junction beta-2 protein Human genes 0.000 description 4
• 208000007569 Giant Cell Tumors Diseases 0.000 description 4
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
• 108010066705 H-cadherin Proteins 0.000 description 4
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 4
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
• 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 4
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 4
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 4
• 102000042838 JAK family Human genes 0.000 description 4
• 108091082332 JAK family Proteins 0.000 description 4
• 206010023825 Laryngeal cancer Diseases 0.000 description 4
• 108010015372 Low Density Lipoprotein Receptor-Related Protein-2 Proteins 0.000 description 4
• 102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 206010029260 Neuroblastoma Diseases 0.000 description 4
• JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
• 102100025803 Progesterone receptor Human genes 0.000 description 4
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
• 208000015634 Rectal Neoplasms Diseases 0.000 description 4
• 102000042833 SYK/ZAP-70 family Human genes 0.000 description 4
• 108091082334 SYK/ZAP-70 family Proteins 0.000 description 4
• 201000010208 Seminoma Diseases 0.000 description 4
• 208000005718 Stomach Neoplasms Diseases 0.000 description 4
• 102100036034 Thrombospondin-1 Human genes 0.000 description 4
• GXVXXETYXSPSOA-UHFFFAOYSA-N Trapoxin A Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCCN2C(=O)C1CC1=CC=CC=C1 GXVXXETYXSPSOA-UHFFFAOYSA-N 0.000 description 4
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
• 208000008383 Wilms tumor Diseases 0.000 description 4
• 230000021736 acetylation Effects 0.000 description 4
• 238000006640 acetylation reaction Methods 0.000 description 4
• 208000017733 acquired polycythemia vera Diseases 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 208000009956 adenocarcinoma Diseases 0.000 description 4
• 201000005188 adrenal gland cancer Diseases 0.000 description 4
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 4
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
• HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 4
• 108010080146 androgen receptors Proteins 0.000 description 4
• 125000003118 aryl group Chemical group 0.000 description 4
• 235000010323 ascorbic acid Nutrition 0.000 description 4
• 229960005070 ascorbic acid Drugs 0.000 description 4
• 239000011668 ascorbic acid Substances 0.000 description 4
• QFFVPLLCYGOFPU-UHFFFAOYSA-N barium chromate Chemical compound [Ba+2].[O-][Cr]([O-])(=O)=O QFFVPLLCYGOFPU-UHFFFAOYSA-N 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 229910002091 carbon monoxide Inorganic materials 0.000 description 4
• 208000002458 carcinoid tumor Diseases 0.000 description 4
• 230000024245 cell differentiation Effects 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 235000015165 citric acid Nutrition 0.000 description 4
• 239000006071 cream Substances 0.000 description 4
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
• HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 4
• 229940104302 cytosine Drugs 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 102000015694 estrogen receptors Human genes 0.000 description 4
• 108010038795 estrogen receptors Proteins 0.000 description 4
• 239000002031 ethanolic fraction Substances 0.000 description 4
• 239000001530 fumaric acid Substances 0.000 description 4
• 235000011087 fumaric acid Nutrition 0.000 description 4
• 229960002598 fumaric acid Drugs 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 201000010175 gallbladder cancer Diseases 0.000 description 4
• 208000001130 gallstones Diseases 0.000 description 4
• 206010017758 gastric cancer Diseases 0.000 description 4
• 210000001035 gastrointestinal tract Anatomy 0.000 description 4
• 210000003714 granulocyte Anatomy 0.000 description 4
• 201000010536 head and neck cancer Diseases 0.000 description 4
• 208000014829 head and neck neoplasm Diseases 0.000 description 4
• 230000002390 hyperplastic effect Effects 0.000 description 4
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical group CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 239000003456 ion exchange resin Substances 0.000 description 4
• 229920003303 ion-exchange polymer Polymers 0.000 description 4
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 4
• 201000002529 islet cell tumor Diseases 0.000 description 4
• 206010023841 laryngeal neoplasm Diseases 0.000 description 4
• 201000010260 leiomyoma Diseases 0.000 description 4
• 201000007270 liver cancer Diseases 0.000 description 4
• 208000014018 liver neoplasm Diseases 0.000 description 4
• 208000037841 lung tumor Diseases 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 239000001630 malic acid Substances 0.000 description 4
• 235000011090 malic acid Nutrition 0.000 description 4
• 229940099690 malic acid Drugs 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 239000002207 metabolite Substances 0.000 description 4
• 229940098779 methanesulfonic acid Drugs 0.000 description 4
• 108090000743 multidrug resistance protein 3 Proteins 0.000 description 4
• 102000004233 multidrug resistance protein 3 Human genes 0.000 description 4
• 201000005962 mycosis fungoides Diseases 0.000 description 4
• VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 4
• XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 4
• 201000008026 nephroblastoma Diseases 0.000 description 4
• 125000004433 nitrogen atom Chemical group N* 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 235000006408 oxalic acid Nutrition 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 4
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
• 229950009215 phenylbutanoic acid Drugs 0.000 description 4
• 239000010452 phosphate Substances 0.000 description 4
• 208000037244 polycythemia vera Diseases 0.000 description 4
• 208000030266 primary brain neoplasm Diseases 0.000 description 4
• 108090000468 progesterone receptors Proteins 0.000 description 4
• 230000009696 proliferative response Effects 0.000 description 4
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 206010038038 rectal cancer Diseases 0.000 description 4
• 201000001275 rectum cancer Diseases 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 239000011347 resin Substances 0.000 description 4
• 229920005989 resin Polymers 0.000 description 4
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 4
• 229960004889 salicylic acid Drugs 0.000 description 4
• 201000000306 sarcoidosis Diseases 0.000 description 4
• 239000000741 silica gel Substances 0.000 description 4
• 229910002027 silica gel Inorganic materials 0.000 description 4
• 239000000600 sorbitol Substances 0.000 description 4
• 235000010356 sorbitol Nutrition 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 201000011549 stomach cancer Diseases 0.000 description 4
• 229910052717 sulfur Inorganic materials 0.000 description 4
• 230000002195 synergetic effect Effects 0.000 description 4
• GXVXXETYXSPSOA-UFEOFEBPSA-N trapoxin A Chemical compound C([C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 GXVXXETYXSPSOA-UFEOFEBPSA-N 0.000 description 4
• 108010060597 trapoxin A Proteins 0.000 description 4
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 3
• ZVEMACCDKBQNGX-KALODSIISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;butanoic acid Chemical compound CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N ZVEMACCDKBQNGX-KALODSIISA-N 0.000 description 3
• JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 3
• VKGQPUZNCZPZKI-UHFFFAOYSA-N (diaminomethylideneamino)azanium;sulfate Chemical compound NN=C(N)N.NN=C(N)N.OS(O)(=O)=O VKGQPUZNCZPZKI-UHFFFAOYSA-N 0.000 description 3
• QRPSQQUYPMFERG-LFYBBSHMSA-N (e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide Chemical compound ONC(=O)\C=C\C#CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 QRPSQQUYPMFERG-LFYBBSHMSA-N 0.000 description 3
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 3
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
• CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 3
• PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 3
• WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 3
• GXIURPTVHJPJLF-UWTATZPHSA-N 2-phospho-D-glyceric acid Chemical compound OC[C@H](C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UWTATZPHSA-N 0.000 description 3
• DGNYDIDAQIEQKM-UHFFFAOYSA-N 3-[(2-amino-6-methylpyrimidin-4-yl)amino]benzoic acid;hydrochloride Chemical compound Cl.NC1=NC(C)=CC(NC=2C=C(C=CC=2)C(O)=O)=N1 DGNYDIDAQIEQKM-UHFFFAOYSA-N 0.000 description 3
• KLWPBEWWHJTYDC-SNAWJCMRSA-N 3-[(e)-2-carboxyethenyl]benzoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(C(O)=O)=C1 KLWPBEWWHJTYDC-SNAWJCMRSA-N 0.000 description 3
• OSJPPGNTCRNQQC-REOHCLBHSA-N 3-phosphoglyceric acid Chemical compound OC(=O)[C@@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-REOHCLBHSA-N 0.000 description 3
• YCYKUNZVKNJOPW-UHFFFAOYSA-N 4-amino-n-(4-nitrophenyl)benzamide Chemical compound C1=CC(N)=CC=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 YCYKUNZVKNJOPW-UHFFFAOYSA-N 0.000 description 3
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 3
• YQYGPGKTNQNXMH-UHFFFAOYSA-N 4-nitroacetophenone Chemical compound CC(=O)C1=CC=C([N+]([O-])=O)C=C1 YQYGPGKTNQNXMH-UHFFFAOYSA-N 0.000 description 3
• 108010044267 Abnormal Hemoglobins Proteins 0.000 description 3
• 206010001233 Adenoma benign Diseases 0.000 description 3
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
• 239000005711 Benzoic acid Substances 0.000 description 3
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 3
• 206010055665 Corneal neovascularisation Diseases 0.000 description 3
• 108010069514 Cyclic Peptides Proteins 0.000 description 3
• 102000001189 Cyclic Peptides Human genes 0.000 description 3
• NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 3
• DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 3
• CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 3
• 102100029588 Deoxycytidine kinase Human genes 0.000 description 3
• 108010033174 Deoxycytidine kinase Proteins 0.000 description 3
• 108010002156 Depsipeptides Proteins 0.000 description 3
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 description 3
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 3
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
• 108091071554 Fes family Proteins 0.000 description 3
• 206010016654 Fibrosis Diseases 0.000 description 3
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
• 208000010412 Glaucoma Diseases 0.000 description 3
• VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• 102000003893 Histone acetyltransferases Human genes 0.000 description 3
• 108090000246 Histone acetyltransferases Proteins 0.000 description 3
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 3
• 208000037147 Hypercalcaemia Diseases 0.000 description 3
• 102000003996 Interferon-beta Human genes 0.000 description 3
• 108090000467 Interferon-beta Proteins 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• 208000007054 Medullary Carcinoma Diseases 0.000 description 3
• PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 description 3
• 108010047956 Nucleosomes Proteins 0.000 description 3
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 3
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 3
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 3
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 3
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
• 229960004909 aminosalicylic acid Drugs 0.000 description 3
• 230000002491 angiogenic effect Effects 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000001093 anti-cancer Effects 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 108010082820 apicidin Proteins 0.000 description 3
• 229930186608 apicidin Natural products 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 235000003704 aspartic acid Nutrition 0.000 description 3
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 3
• 229940092714 benzenesulfonic acid Drugs 0.000 description 3
• 235000010233 benzoic acid Nutrition 0.000 description 3
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
• 230000003115 biocidal effect Effects 0.000 description 3
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
• 238000004364 calculation method Methods 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 150000001768 cations Chemical class 0.000 description 3
• 230000006020 chronic inflammation Effects 0.000 description 3
• 230000001886 ciliary effect Effects 0.000 description 3
• 235000013985 cinnamic acid Nutrition 0.000 description 3
• 229930016911 cinnamic acid Natural products 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 201000000159 corneal neovascularization Diseases 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 3
• UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 230000004761 fibrosis Effects 0.000 description 3
• 239000012362 glacial acetic acid Substances 0.000 description 3
• 208000005017 glioblastoma Diseases 0.000 description 3
• 239000000174 gluconic acid Substances 0.000 description 3
• 235000012208 gluconic acid Nutrition 0.000 description 3
• 229940097043 glucuronic acid Drugs 0.000 description 3
• 235000013922 glutamic acid Nutrition 0.000 description 3
• 239000004220 glutamic acid Substances 0.000 description 3
• FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 3
• 230000000148 hypercalcaemia Effects 0.000 description 3
• 208000030915 hypercalcemia disease Diseases 0.000 description 3
• 229960003685 imatinib mesylate Drugs 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 230000004941 influx Effects 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 229940079322 interferon Drugs 0.000 description 3
• 229940047124 interferons Drugs 0.000 description 3
• 229940047122 interleukins Drugs 0.000 description 3
• 230000002427 irreversible effect Effects 0.000 description 3
• 206010023332 keratitis Diseases 0.000 description 3
• 239000004310 lactic acid Substances 0.000 description 3
• 235000014655 lactic acid Nutrition 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
• 239000011976 maleic acid Substances 0.000 description 3
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 3
• 229960002510 mandelic acid Drugs 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• CHMBIJAOCISYEW-UHFFFAOYSA-N n-(4-aminophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(N)C=C1 CHMBIJAOCISYEW-UHFFFAOYSA-N 0.000 description 3
• NSCFHVXOVBMGAK-UHFFFAOYSA-N n-phenylquinolin-2-amine Chemical compound C=1C=C2C=CC=CC2=NC=1NC1=CC=CC=C1 NSCFHVXOVBMGAK-UHFFFAOYSA-N 0.000 description 3
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 3
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 229960003512 nicotinic acid Drugs 0.000 description 3
• 239000011664 nicotinic acid Substances 0.000 description 3
• 235000001968 nicotinic acid Nutrition 0.000 description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
• 210000001623 nucleosome Anatomy 0.000 description 3
• 150000007524 organic acids Chemical class 0.000 description 3
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 3
• 208000028591 pheochromocytoma Diseases 0.000 description 3
• 210000004214 philadelphia chromosome Anatomy 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 150000003248 quinolines Chemical class 0.000 description 3
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 239000002002 slurry Substances 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 230000000392 somatic effect Effects 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 239000011975 tartaric acid Substances 0.000 description 3
• 235000002906 tartaric acid Nutrition 0.000 description 3
• 230000005758 transcription activity Effects 0.000 description 3
• 230000005945 translocation Effects 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
• 231100000397 ulcer Toxicity 0.000 description 3
• OTXHZHQQWQTQMW-UHFFFAOYSA-N (diaminomethylideneamino)azanium;hydrogen carbonate Chemical compound OC([O-])=O.N[NH2+]C(N)=N OTXHZHQQWQTQMW-UHFFFAOYSA-N 0.000 description 2
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
• 102100027833 14-3-3 protein sigma Human genes 0.000 description 2
• 238000005160 1H NMR spectroscopy Methods 0.000 description 2
• VMRCHEBYEJBVOS-UHFFFAOYSA-N 2,3,4-trifluoroquinoline Chemical compound C1=CC=C2C(F)=C(F)C(F)=NC2=C1 VMRCHEBYEJBVOS-UHFFFAOYSA-N 0.000 description 2
• KWVNKWCJDAWNAE-UHFFFAOYSA-N 2,3-dichloroquinoline Chemical compound C1=CC=C2N=C(Cl)C(Cl)=CC2=C1 KWVNKWCJDAWNAE-UHFFFAOYSA-N 0.000 description 2
• QDAWXRKTSATEOP-UHFFFAOYSA-N 2-acetylbenzoic acid Chemical compound CC(=O)C1=CC=CC=C1C(O)=O QDAWXRKTSATEOP-UHFFFAOYSA-N 0.000 description 2
• JTWHVBNYYWFXSI-UHFFFAOYSA-N 2-nitro-1-phenylethanone Chemical compound [O-][N+](=O)CC(=O)C1=CC=CC=C1 JTWHVBNYYWFXSI-UHFFFAOYSA-N 0.000 description 2
• OHWLDHSSZYNNLN-UHFFFAOYSA-M 2-pyridin-1-ium-1-ylpyridine;chloride Chemical compound [Cl-].C1=CC=CC=[N+]1C1=CC=CC=N1 OHWLDHSSZYNNLN-UHFFFAOYSA-M 0.000 description 2
• CVODRSLGNPVRBR-UHFFFAOYSA-N 3-[(2,6-diaminopyrimidin-4-yl)amino]-n-[4-[(6-nitroquinolin-4-yl)amino]phenyl]benzamide;dihydrochloride Chemical compound Cl.Cl.NC1=NC(N)=CC(NC=2C=C(C=CC=2)C(=O)NC=2C=CC(NC=3C4=CC(=CC=C4N=CC=3)[N+]([O-])=O)=CC=2)=N1 CVODRSLGNPVRBR-UHFFFAOYSA-N 0.000 description 2
• AHRTWCXZYMMRPD-UHFFFAOYSA-N 3-[(2-amino-6-methylpyrimidin-4-yl)amino]-n-[4-(quinolin-4-ylamino)phenyl]benzamide;dihydrochloride Chemical compound Cl.Cl.NC1=NC(C)=CC(NC=2C=C(C=CC=2)C(=O)NC=2C=CC(NC=3C4=CC=CC=C4N=CC=3)=CC=2)=N1 AHRTWCXZYMMRPD-UHFFFAOYSA-N 0.000 description 2
• CHZPJUSFUDUEMZ-UHFFFAOYSA-N 3-acetylbenzoic acid Chemical compound CC(=O)C1=CC=CC(C(O)=O)=C1 CHZPJUSFUDUEMZ-UHFFFAOYSA-N 0.000 description 2
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
• ZMNNEWXIZKVAJR-UHFFFAOYSA-N 4,5,6-trifluoro-2-oxo-1h-quinoline-3-carboxylic acid Chemical compound FC1=CC=C2NC(=O)C(C(=O)O)=C(F)C2=C1F ZMNNEWXIZKVAJR-UHFFFAOYSA-N 0.000 description 2
• VIJLMEUQVUTXEE-UHFFFAOYSA-N 4-[(1-methylpyridin-1-ium-4-yl)amino]-n-(4-nitrophenyl)benzamide;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1NC1=CC=C(C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)C=C1 VIJLMEUQVUTXEE-UHFFFAOYSA-N 0.000 description 2
• UTURXNCXZHSZTM-UHFFFAOYSA-N 4-[(2-amino-6-methylpyrimidin-4-yl)amino]-n-[4-(quinolin-4-ylamino)phenyl]benzamide;dihydrochloride Chemical compound Cl.Cl.NC1=NC(C)=CC(NC=2C=CC(=CC=2)C(=O)NC=2C=CC(NC=3C4=CC=CC=C4N=CC=3)=CC=2)=N1 UTURXNCXZHSZTM-UHFFFAOYSA-N 0.000 description 2
• OQESMIXYDCPOQR-UHFFFAOYSA-N 4-[(2-amino-6-methylpyrimidin-4-yl)amino]-n-[4-[[6-(dimethylamino)quinolin-4-yl]amino]phenyl]benzamide;dihydrochloride Chemical compound Cl.Cl.C12=CC(N(C)C)=CC=C2N=CC=C1NC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1NC1=CC(C)=NC(N)=N1 OQESMIXYDCPOQR-UHFFFAOYSA-N 0.000 description 2
• QBHDSQZASIBAAI-UHFFFAOYSA-N 4-acetylbenzoic acid Chemical compound CC(=O)C1=CC=C(C(O)=O)C=C1 QBHDSQZASIBAAI-UHFFFAOYSA-N 0.000 description 2
• RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 2
• RWHYGYAFFWXQSX-UHFFFAOYSA-N 4-n-(4-aminophenyl)-6-n,6-n-dimethylquinolin-1-ium-4,6-diamine;chloride Chemical compound [Cl-].C12=CC(N(C)C)=CC=C2[NH+]=CC=C1NC1=CC=C(N)C=C1 RWHYGYAFFWXQSX-UHFFFAOYSA-N 0.000 description 2
• OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 2
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 2
• KDHRJRWXPVNWPI-UHFFFAOYSA-N 6-(dimethylamino)-3h-quinolin-4-one Chemical compound N1=CCC(=O)C2=CC(N(C)C)=CC=C21 KDHRJRWXPVNWPI-UHFFFAOYSA-N 0.000 description 2
• BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 2
• FAVJCKFTOWIVRB-UHFFFAOYSA-N 6-amino-3h-quinolin-4-one Chemical compound N1=CCC(=O)C2=CC(N)=CC=C21 FAVJCKFTOWIVRB-UHFFFAOYSA-N 0.000 description 2
• QJIUMVUZDYPQRT-UHFFFAOYSA-N 6-chloro-2,4-pyrimidinediamine Chemical compound NC1=CC(Cl)=NC(N)=N1 QJIUMVUZDYPQRT-UHFFFAOYSA-N 0.000 description 2
• NRRRWEKUOZJLBY-UHFFFAOYSA-N 6-chloro-3h-quinolin-4-one Chemical compound N1=CCC(=O)C2=CC(Cl)=CC=C21 NRRRWEKUOZJLBY-UHFFFAOYSA-N 0.000 description 2
• 206010000830 Acute leukaemia Diseases 0.000 description 2
• 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 102100025982 BMP/retinoic acid-inducible neural-specific protein 1 Human genes 0.000 description 2
• 108700020463 BRCA1 Proteins 0.000 description 2
• 102000036365 BRCA1 Human genes 0.000 description 2
• 101150072950 BRCA1 gene Proteins 0.000 description 2
• 102100037674 Bis(5'-adenosyl)-triphosphatase Human genes 0.000 description 2
• 102100032912 CD44 antigen Human genes 0.000 description 2
• 102000000905 Cadherin Human genes 0.000 description 2
• 108050007957 Cadherin Proteins 0.000 description 2
• 102000055006 Calcitonin Human genes 0.000 description 2
• 108060001064 Calcitonin Proteins 0.000 description 2
• 102100038518 Calcitonin Human genes 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 241000189662 Calla Species 0.000 description 2
• 108090000538 Caspase-8 Proteins 0.000 description 2
• 102000003727 Caveolin 1 Human genes 0.000 description 2
• 108090000026 Caveolin 1 Proteins 0.000 description 2
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
• 108010069156 Connexin 26 Proteins 0.000 description 2
• 206010011017 Corneal graft rejection Diseases 0.000 description 2
• 102000008160 Cyclin A1 Human genes 0.000 description 2
• 108010060267 Cyclin A1 Proteins 0.000 description 2
• 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 2
• 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
• 102000004480 Cyclin-Dependent Kinase Inhibitor p57 Human genes 0.000 description 2
• 108010017222 Cyclin-Dependent Kinase Inhibitor p57 Proteins 0.000 description 2
• 102100033233 Cyclin-dependent kinase inhibitor 1B Human genes 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
• 101150016325 EPHA3 gene Proteins 0.000 description 2
• 102000013128 Endothelin B Receptor Human genes 0.000 description 2
• 108010090557 Endothelin B Receptor Proteins 0.000 description 2
• 208000004232 Enteritis Diseases 0.000 description 2
• 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 2
• 101710100588 Erythroid transcription factor Proteins 0.000 description 2
• 102100031690 Erythroid transcription factor Human genes 0.000 description 2
• 108091008794 FGF receptors Proteins 0.000 description 2
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
• 208000003098 Ganglion Cysts Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102000010956 Glypican Human genes 0.000 description 2
• 108050001154 Glypican Proteins 0.000 description 2
• 102100032530 Glypican-3 Human genes 0.000 description 2
• 108050007237 Glypican-3 Proteins 0.000 description 2
• 108091005886 Hemoglobin subunit gamma Proteins 0.000 description 2
• 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 2
• RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
• 102100025110 Homeobox protein Hox-A5 Human genes 0.000 description 2
• 101000723509 Homo sapiens 14-3-3 protein sigma Proteins 0.000 description 2
• 101000933342 Homo sapiens BMP/retinoic acid-inducible neural-specific protein 1 Proteins 0.000 description 2
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
• 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 2
• 101000932890 Homo sapiens Calcitonin gene-related peptide 1 Proteins 0.000 description 2
• 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 2
• 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 2
• 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 2
• 101001077568 Homo sapiens Homeobox protein Hox-A5 Proteins 0.000 description 2
• 101000993380 Homo sapiens Hypermethylated in cancer 1 protein Proteins 0.000 description 2
• 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 description 2
• 101100236208 Homo sapiens LTB4R gene Proteins 0.000 description 2
• 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 2
• 101001023043 Homo sapiens Myoblast determination protein 1 Proteins 0.000 description 2
• 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
• 101000712958 Homo sapiens Ras association domain-containing protein 1 Proteins 0.000 description 2
• 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 2
• 101000762128 Homo sapiens Tumor suppressor candidate 3 Proteins 0.000 description 2
• 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 2
• 101000860430 Homo sapiens Versican core protein Proteins 0.000 description 2
• 102100031612 Hypermethylated in cancer 1 protein Human genes 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102100038070 Interferon regulatory factor 7 Human genes 0.000 description 2
• 102000013462 Interleukin-12 Human genes 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000004388 Interleukin-4 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 description 2
• 102000003680 Leukotriene B4 receptors Human genes 0.000 description 2
• 108090000093 Leukotriene B4 receptors Proteins 0.000 description 2
• 208000001826 Marfan syndrome Diseases 0.000 description 2
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
• 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 2
• 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 2
• 208000016285 Movement disease Diseases 0.000 description 2
• 102100034263 Mucin-2 Human genes 0.000 description 2
• 206010062207 Mycobacterial infection Diseases 0.000 description 2
• 102100035077 Myoblast determination protein 1 Human genes 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• 206010029113 Neovascularisation Diseases 0.000 description 2
• 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 2
• 108010032788 PAX6 Transcription Factor Proteins 0.000 description 2
• 108091008606 PDGF receptors Proteins 0.000 description 2
• 102100037506 Paired box protein Pax-6 Human genes 0.000 description 2
• 102100035220 Plastin-3 Human genes 0.000 description 2
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 108091008611 Protein Kinase B Proteins 0.000 description 2
• 102000055027 Protein Methyltransferases Human genes 0.000 description 2
• 108700040121 Protein Methyltransferases Proteins 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 102100033243 Ras association domain-containing protein 1 Human genes 0.000 description 2
• 230000018199 S phase Effects 0.000 description 2
• 101100437750 Schizosaccharomyces pombe (strain 972 / ATCC 24843) blt1 gene Proteins 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 208000005400 Synovial Cyst Diseases 0.000 description 2
• 102100030306 TBC1 domain family member 9 Human genes 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 102100035115 Testin Human genes 0.000 description 2
• 101710070533 Testin Proteins 0.000 description 2
• 108010046722 Thrombospondin 1 Proteins 0.000 description 2
• 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 2
• 102100024248 Tumor suppressor candidate 3 Human genes 0.000 description 2
• 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 2
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
• 102100028437 Versican core protein Human genes 0.000 description 2
• 125000002447 acetohydrazonoyl group Chemical group [H]C([H])([H])C([*])=NN([H])[H] 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 150000001447 alkali salts Chemical class 0.000 description 2
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
• 229940100609 all-trans-retinol Drugs 0.000 description 2
• 239000011717 all-trans-retinol Substances 0.000 description 2
• 235000019169 all-trans-retinol Nutrition 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 229960004050 aminobenzoic acid Drugs 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 229960005261 aspartic acid Drugs 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
• 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 2
• 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 108010005713 bis(5'-adenosyl)triphosphatase Proteins 0.000 description 2
• 201000000053 blastoma Diseases 0.000 description 2
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
• 229960004015 calcitonin Drugs 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
• 150000001735 carboxylic acids Chemical class 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 2
• 239000012050 conventional carrier Substances 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 239000007822 coupling agent Substances 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• OJXVEMFXDVJJSA-KYEJVWEESA-N diaminomethylidene-[(e)-1-[3-[[4-[[6-(dimethylamino)quinolin-4-yl]amino]phenyl]carbamoyl]phenyl]ethylideneamino]azanium;chloride Chemical compound [Cl-].C12=CC(N(C)C)=CC=C2[NH+]=CC=C1NC(C=C1)=CC=C1NC(=O)C1=CC=CC(C(\C)=N\N=C(N)N)=C1 OJXVEMFXDVJJSA-KYEJVWEESA-N 0.000 description 2
• 235000015872 dietary supplement Nutrition 0.000 description 2
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
• 239000003968 dna methyltransferase inhibitor Substances 0.000 description 2
• 201000008184 embryoma Diseases 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 238000012226 gene silencing method Methods 0.000 description 2
• 229960002989 glutamic acid Drugs 0.000 description 2
• 239000003966 growth inhibitor Substances 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• 229940022353 herceptin Drugs 0.000 description 2
• 230000006197 histone deacetylation Effects 0.000 description 2
• 229940125697 hormonal agent Drugs 0.000 description 2
• 150000003840 hydrochlorides Chemical class 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 230000006607 hypermethylation Effects 0.000 description 2
• 230000002584 immunomodulator Effects 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 239000003978 infusion fluid Substances 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 229940117681 interleukin-12 Drugs 0.000 description 2
• 229940028885 interleukin-4 Drugs 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 230000007794 irritation Effects 0.000 description 2
• 229960005280 isotretinoin Drugs 0.000 description 2
• 201000010666 keratoconjunctivitis Diseases 0.000 description 2
• 229940043355 kinase inhibitor Drugs 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 239000012669 liquid formulation Substances 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 210000005075 mammary gland Anatomy 0.000 description 2
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 150000002739 metals Chemical class 0.000 description 2
• 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 2
• 210000004877 mucosa Anatomy 0.000 description 2
• 208000027531 mycobacterial infectious disease Diseases 0.000 description 2
• BSBYBAQRPWSERQ-UHFFFAOYSA-N n-(4-nitrophenyl)-3-(pyridin-4-ylamino)benzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(=O)C1=CC=CC(NC=2C=CN=CC=2)=C1 BSBYBAQRPWSERQ-UHFFFAOYSA-N 0.000 description 2
• OPPIVTKJZWGFTP-UHFFFAOYSA-N n-(4-nitrophenyl)-4-(pyridin-4-ylamino)benzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(=O)C(C=C1)=CC=C1NC1=CC=NC=C1 OPPIVTKJZWGFTP-UHFFFAOYSA-N 0.000 description 2
• NAIFAOOFUVATIX-UHFFFAOYSA-N n-[3-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]-4-(quinolin-4-ylamino)benzamide;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1NC1=CC=CC(NC(=O)C=2C=CC(NC=3C4=CC=CC=C4N=CC=3)=CC=2)=C1 NAIFAOOFUVATIX-UHFFFAOYSA-N 0.000 description 2
• GGWOGEAVNAPMLB-UHFFFAOYSA-N n-[3-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]-4-(quinolin-4-ylamino)benzamide;hydrochloride Chemical compound Cl.NC1=NC(C)=CC(NC=2C=C(NC(=O)C=3C=CC(NC=4C5=CC=CC=C5N=CC=4)=CC=3)C=CC=2)=N1 GGWOGEAVNAPMLB-UHFFFAOYSA-N 0.000 description 2
• BTWGHACHPBOCOB-UHFFFAOYSA-N n-[4-(pyridin-4-ylamino)phenyl]-4-(quinolin-4-ylamino)benzamide Chemical compound C=1C=C(NC=2C3=CC=CC=C3N=CC=2)C=CC=1C(=O)NC(C=C1)=CC=C1NC1=CC=NC=C1 BTWGHACHPBOCOB-UHFFFAOYSA-N 0.000 description 2
• BNSDHXXQYYZOJS-UHFFFAOYSA-N n-[4-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]-4-(quinolin-4-ylamino)benzamide;hydrochloride Chemical compound Cl.NC1=NC(C)=CC(NC=2C=CC(NC(=O)C=3C=CC(NC=4C5=CC=CC=C5N=CC=4)=CC=3)=CC=2)=N1 BNSDHXXQYYZOJS-UHFFFAOYSA-N 0.000 description 2
• GAJPGLDHAQJFHZ-UHFFFAOYSA-N n-[4-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]-4-[(6-nitroquinolin-4-yl)amino]benzamide;hydrochloride Chemical compound Cl.NC1=NC(C)=CC(NC=2C=CC(NC(=O)C=3C=CC(NC=4C5=CC(=CC=C5N=CC=4)[N+]([O-])=O)=CC=3)=CC=2)=N1 GAJPGLDHAQJFHZ-UHFFFAOYSA-N 0.000 description 2
• LKMZSRTWIHLQOC-UHFFFAOYSA-N n-[4-[(6-aminoquinolin-4-yl)amino]phenyl]-4-[(1-methylpyridin-1-ium-4-yl)amino]benzamide;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1NC1=CC=C(C(=O)NC=2C=CC(NC=3C4=CC(N)=CC=C4N=CC=3)=CC=2)C=C1 LKMZSRTWIHLQOC-UHFFFAOYSA-N 0.000 description 2
• OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 description 2
• 239000006225 natural substrate Substances 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 239000002777 nucleoside Substances 0.000 description 2
• 150000003833 nucleoside derivatives Chemical class 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000006186 oral dosage form Substances 0.000 description 2
• 210000004789 organ system Anatomy 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 235000011007 phosphoric acid Nutrition 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• 108010049148 plastin Proteins 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 235000019260 propionic acid Nutrition 0.000 description 2
• 235000013772 propylene glycol Nutrition 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
• ZUUVLQLFGXMSDI-UHFFFAOYSA-N quinolin-1-ium dichloride Chemical compound [Cl-].[Cl-].[NH+]1=CC=CC2=CC=CC=C12.[NH+]1=CC=CC2=CC=CC=C12 ZUUVLQLFGXMSDI-UHFFFAOYSA-N 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 230000003252 repetitive effect Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000000754 repressing effect Effects 0.000 description 2
• 230000002207 retinal effect Effects 0.000 description 2
• 229960004641 rituximab Drugs 0.000 description 2
• 229960003452 romidepsin Drugs 0.000 description 2
• OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
• 108010091666 romidepsin Proteins 0.000 description 2
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
• 235000021391 short chain fatty acids Nutrition 0.000 description 2
• 150000004666 short chain fatty acids Chemical class 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 108010013351 sodium-iodide symporter Proteins 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 150000003460 sulfonic acids Chemical class 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 208000006379 syphilis Diseases 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
• 239000006208 topical dosage form Substances 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 125000005208 trialkylammonium group Chemical group 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
• 229960005356 urokinase Drugs 0.000 description 2
• WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
• XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
• OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• ARKIFHPFTHVKDT-UHFFFAOYSA-N 1-(3-nitrophenyl)ethanone Chemical compound CC(=O)C1=CC=CC([N+]([O-])=O)=C1 ARKIFHPFTHVKDT-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• IIELZHYJYZBSGG-UHFFFAOYSA-N 10-(3-aminopropyl)-3,4-dimethylacridin-9-one;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3N(CCCN)C2=C1 IIELZHYJYZBSGG-UHFFFAOYSA-N 0.000 description 1
• ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
• RVZMPNMUBCAPQO-UHFFFAOYSA-N 2,4-dimethoxyquinazoline Chemical class C1=CC=CC2=NC(OC)=NC(OC)=C21 RVZMPNMUBCAPQO-UHFFFAOYSA-N 0.000 description 1
• MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
• GTKDJUMUMSCFGV-UHFFFAOYSA-N 2-acetamido-n-(4-nitrophenyl)benzamide Chemical compound CC(=O)NC1=CC=CC=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GTKDJUMUMSCFGV-UHFFFAOYSA-N 0.000 description 1
• CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 1
• UDAIGHZFMLGNDQ-UHFFFAOYSA-N 2-nitroquinoline Chemical compound C1=CC=CC2=NC([N+](=O)[O-])=CC=C21 UDAIGHZFMLGNDQ-UHFFFAOYSA-N 0.000 description 1
• DFOUTGGPUPHEMO-UHFFFAOYSA-N 2-pyridin-1-ium-4-ylpyridine;chloride Chemical compound Cl.N1=CC=CC=C1C1=CC=NC=C1 DFOUTGGPUPHEMO-UHFFFAOYSA-N 0.000 description 1
• RMHQDKYZXJVCME-UHFFFAOYSA-N 2-pyridin-4-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=NC=C1 RMHQDKYZXJVCME-UHFFFAOYSA-N 0.000 description 1
• IOAPNOOBYBCVEH-UHFFFAOYSA-N 3,4,5-trifluoro-1h-quinolin-2-one Chemical compound N1C(=O)C(F)=C(F)C2=C1C=CC=C2F IOAPNOOBYBCVEH-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• MHDWEJIKZLVHIQ-UHFFFAOYSA-N 3-[(1-methylpyridin-1-ium-4-yl)amino]-n-(4-nitrophenyl)benzamide;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1NC1=CC=CC(C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)=C1 MHDWEJIKZLVHIQ-UHFFFAOYSA-N 0.000 description 1
• QNESGIBHIJDLOH-UHFFFAOYSA-N 3-[(2,6-diaminopyrimidin-4-yl)amino]-n-(4-nitrophenyl)benzamide;hydrochloride Chemical compound Cl.NC1=NC(N)=CC(NC=2C=C(C=CC=2)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)=N1 QNESGIBHIJDLOH-UHFFFAOYSA-N 0.000 description 1
• XQNXKPNXXIAGQM-UHFFFAOYSA-N 3-[(2,6-diaminopyrimidin-4-yl)amino]-n-[4-(quinolin-4-ylamino)phenyl]benzamide;dihydrochloride Chemical compound Cl.Cl.NC1=NC(N)=CC(NC=2C=C(C=CC=2)C(=O)NC=2C=CC(NC=3C4=CC=CC=C4N=CC=3)=CC=2)=N1 XQNXKPNXXIAGQM-UHFFFAOYSA-N 0.000 description 1
• OPPXQPXYAODZQS-UHFFFAOYSA-N 3-[(2-amino-6-methylpyrimidin-4-yl)amino]-n-(4-aminophenyl)benzamide;hydrochloride Chemical compound Cl.NC1=NC(C)=CC(NC=2C=C(C=CC=2)C(=O)NC=2C=CC(N)=CC=2)=N1 OPPXQPXYAODZQS-UHFFFAOYSA-N 0.000 description 1
• LQQQNINGEGVNIT-UHFFFAOYSA-N 3-[(2-amino-6-methylpyrimidin-4-yl)amino]-n-(4-nitrophenyl)benzamide;hydrochloride Chemical compound Cl.NC1=NC(C)=CC(NC=2C=C(C=CC=2)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)=N1 LQQQNINGEGVNIT-UHFFFAOYSA-N 0.000 description 1
• NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
• RGDPZMQZWZMONQ-UHFFFAOYSA-N 3-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=CC(C(O)=O)=C1 RGDPZMQZWZMONQ-UHFFFAOYSA-N 0.000 description 1
• LKXKSEXXHHGHQP-UHFFFAOYSA-N 3-acetyl-n-[4-[[6-(dimethylamino)quinolin-1-ium-4-yl]amino]phenyl]benzamide;chloride Chemical compound [Cl-].C12=CC(N(C)C)=CC=C2[NH+]=CC=C1NC(C=C1)=CC=C1NC(=O)C1=CC=CC(C(C)=O)=C1 LKXKSEXXHHGHQP-UHFFFAOYSA-N 0.000 description 1
• VVUXXNFYPNKDJY-UHFFFAOYSA-N 3-n-pyridin-4-ylbenzene-1,3-diamine Chemical compound NC1=CC=CC(NC=2C=CN=CC=2)=C1 VVUXXNFYPNKDJY-UHFFFAOYSA-N 0.000 description 1
• JZGUMSTXLPEMFW-UHFFFAOYSA-N 4,6-dichloroquinoline Chemical compound N1=CC=C(Cl)C2=CC(Cl)=CC=C21 JZGUMSTXLPEMFW-UHFFFAOYSA-N 0.000 description 1
• NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
• OEWZQATXQINCCC-UHFFFAOYSA-N 4-(pyridin-4-ylamino)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=CC=NC=C1 OEWZQATXQINCCC-UHFFFAOYSA-N 0.000 description 1
• DJLRBZKHMSZMAZ-UHFFFAOYSA-N 4-[(1-methylpyridin-1-ium-4-yl)amino]-n-[4-[(6-nitroquinolin-4-yl)amino]phenyl]benzamide;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1NC1=CC=C(C(=O)NC=2C=CC(NC=3C4=CC(=CC=C4N=CC=3)[N+]([O-])=O)=CC=2)C=C1 DJLRBZKHMSZMAZ-UHFFFAOYSA-N 0.000 description 1
• YDAJZDXRALGOEO-UHFFFAOYSA-N 4-[(2-amino-6-methylpyrimidin-4-yl)amino]-n-(4-aminophenyl)benzamide Chemical compound NC1=NC(C)=CC(NC=2C=CC(=CC=2)C(=O)NC=2C=CC(N)=CC=2)=N1 YDAJZDXRALGOEO-UHFFFAOYSA-N 0.000 description 1
• JDFPXKJJWFMUMK-UHFFFAOYSA-N 4-[(2-amino-6-methylpyrimidin-4-yl)amino]-n-[4-[(6-nitroquinolin-4-yl)amino]phenyl]benzamide;dihydrochloride Chemical compound Cl.Cl.NC1=NC(C)=CC(NC=2C=CC(=CC=2)C(=O)NC=2C=CC(NC=3C4=CC(=CC=C4N=CC=3)[N+]([O-])=O)=CC=2)=N1 JDFPXKJJWFMUMK-UHFFFAOYSA-N 0.000 description 1
• DLSGGDKVIWSMFL-UHFFFAOYSA-N 4-[(2-amino-6-methylpyrimidin-4-yl)amino]-n-[4-[(7-nitroquinolin-4-yl)amino]phenyl]benzamide;dihydrochloride Chemical compound Cl.Cl.NC1=NC(C)=CC(NC=2C=CC(=CC=2)C(=O)NC=2C=CC(NC=3C4=CC=C(C=C4N=CC=3)[N+]([O-])=O)=CC=2)=N1 DLSGGDKVIWSMFL-UHFFFAOYSA-N 0.000 description 1
• NKOIDEAUWOAYRS-UHFFFAOYSA-N 4-[(6-amino-1-methylquinolin-1-ium-4-yl)amino]-n-[4-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]benzamide;dibromide Chemical compound [Br-].[Br-].C1=C[N+](C)=CC=C1NC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1NC1=CC=[N+](C)C2=CC=C(N)C=C12 NKOIDEAUWOAYRS-UHFFFAOYSA-N 0.000 description 1
• MIVGKMLPVUMVSG-AWFSDRIXSA-N 4-[(e)-n-(diaminomethylideneamino)-c-methylcarbonimidoyl]benzoic acid;hydrochloride Chemical compound Cl.NC(N)=N\N=C(/C)C1=CC=C(C(O)=O)C=C1 MIVGKMLPVUMVSG-AWFSDRIXSA-N 0.000 description 1
• LWCUJJTZUMQSAH-UHFFFAOYSA-N 4-amino-n-[3-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]benzamide Chemical compound NC1=NC(C)=CC(NC=2C=C(NC(=O)C=3C=CC(N)=CC=3)C=CC=2)=N1 LWCUJJTZUMQSAH-UHFFFAOYSA-N 0.000 description 1
• GBIUYQOKDICWQL-UHFFFAOYSA-N 4-amino-n-[4-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]benzamide;hydrochloride Chemical compound Cl.NC1=NC(C)=CC(NC=2C=CC(NC(=O)C=3C=CC(N)=CC=3)=CC=2)=N1 GBIUYQOKDICWQL-UHFFFAOYSA-N 0.000 description 1
• AQQUDAZEGZKHGB-GDUPHPTFSA-N 4-amino-n-[4-[(e)-n-(diaminomethylideneamino)-c-methylcarbonimidoyl]phenyl]benzamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(C(=N/N=C(N)N)/C)=CC=C1NC(=O)C1=CC=C(N)C=C1 AQQUDAZEGZKHGB-GDUPHPTFSA-N 0.000 description 1
• GCGDQNKFLFUHBN-UHFFFAOYSA-N 4-chloro-6,7,8-trifluoroquinoline Chemical compound C1=CN=C2C(F)=C(F)C(F)=CC2=C1Cl GCGDQNKFLFUHBN-UHFFFAOYSA-N 0.000 description 1
• 150000005653 4-chloroquinolines Chemical class 0.000 description 1
• MKNCMEZNCBQVHZ-UHFFFAOYSA-N 4-methylbenzenesulfonate;3-[(1-methylpyridin-1-ium-4-yl)amino]-n-(4-nitrophenyl)benzamide Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=C[N+](C)=CC=C1NC1=CC=CC(C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)=C1 MKNCMEZNCBQVHZ-UHFFFAOYSA-N 0.000 description 1
• GCVFWEODJMQBDH-UHFFFAOYSA-N 4-n-(3-aminophenyl)-6-methylpyrimidine-2,4-diamine Chemical compound NC1=NC(C)=CC(NC=2C=C(N)C=CC=2)=N1 GCVFWEODJMQBDH-UHFFFAOYSA-N 0.000 description 1
• GBLLEQWOEDKFBX-UHFFFAOYSA-N 4-n-(4-aminophenyl)-6-methylpyrimidine-2,4-diamine Chemical compound NC1=NC(C)=CC(NC=2C=CC(N)=CC=2)=N1 GBLLEQWOEDKFBX-UHFFFAOYSA-N 0.000 description 1
• BGFGRYYEROKAHI-UHFFFAOYSA-N 4-n-pyridin-4-ylbenzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1NC1=CC=NC=C1 BGFGRYYEROKAHI-UHFFFAOYSA-N 0.000 description 1
• IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
• MMRCWWRFYLZGAE-ZBZRSYSASA-N 533u947v6q Chemical compound O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O MMRCWWRFYLZGAE-ZBZRSYSASA-N 0.000 description 1
• KEOLWQHYWNESLY-UHFFFAOYSA-N 6,7,8-trifluoro-1h-quinolin-4-one Chemical compound FC1=C(F)C(F)=CC2=C1NC=CC2=O KEOLWQHYWNESLY-UHFFFAOYSA-N 0.000 description 1
• QHDWSQNLUDZXKQ-UHFFFAOYSA-N 6,7,8-trifluoro-4-oxo-1h-quinoline-3-carboxylic acid Chemical compound FC1=C(F)C(F)=CC2=C(O)C(C(=O)O)=CN=C21 QHDWSQNLUDZXKQ-UHFFFAOYSA-N 0.000 description 1
• LEOLUDLEZDOIID-UHFFFAOYSA-N 6-methyl-4-n-(3-nitrophenyl)pyrimidine-2,4-diamine Chemical compound NC1=NC(C)=CC(NC=2C=C(C=CC=2)[N+]([O-])=O)=N1 LEOLUDLEZDOIID-UHFFFAOYSA-N 0.000 description 1
• SVNRNDIBXIDKSU-UHFFFAOYSA-N 6-methyl-4-n-(4-nitrophenyl)pyrimidine-2,4-diamine Chemical compound NC1=NC(C)=CC(NC=2C=CC(=CC=2)[N+]([O-])=O)=N1 SVNRNDIBXIDKSU-UHFFFAOYSA-N 0.000 description 1
• FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
• SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 206010000060 Abdominal distension Diseases 0.000 description 1
• GDALETGZDYOOGB-UHFFFAOYSA-N Acridone Natural products C1=C(O)C=C2N(C)C3=CC=CC=C3C(=O)C2=C1O GDALETGZDYOOGB-UHFFFAOYSA-N 0.000 description 1
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
• 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
• 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical group C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 208000005692 Bloom Syndrome Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• GOQFVUGBLOWPCE-UHFFFAOYSA-N BrC=1C=C(C=C(C1O)Br)C1=NC(=NC2=CC(=C(C=C12)OC)OC)N Chemical compound BrC=1C=C(C=C(C1O)Br)C1=NC(=NC2=CC(=C(C=C12)OC)OC)N GOQFVUGBLOWPCE-UHFFFAOYSA-N 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 208000003163 Cavernous Hemangioma Diseases 0.000 description 1
• 206010051290 Central nervous system lesion Diseases 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 208000009043 Chemical Burns Diseases 0.000 description 1
• 208000018380 Chemical injury Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 208000002691 Choroiditis Diseases 0.000 description 1
• 241000588879 Chromobacterium violaceum Species 0.000 description 1
• 208000037088 Chromosome Breakage Diseases 0.000 description 1
• 208000036086 Chromosome Duplication Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 206010010144 Completed suicide Diseases 0.000 description 1
• 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 108091029523 CpG island Proteins 0.000 description 1
• 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 1
• 108091007045 Cullin Ring E3 Ligases Proteins 0.000 description 1
• 201000005171 Cystadenoma Diseases 0.000 description 1
• 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
• 230000006429 DNA hypomethylation Effects 0.000 description 1
• 229940096395 DNA methylase inhibitor Drugs 0.000 description 1
• 230000030933 DNA methylation on cytosine Effects 0.000 description 1
• 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 1
• 206010011985 Decubitus ulcer Diseases 0.000 description 1
• DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
• FVIGODVHAVLZOO-UHFFFAOYSA-N Dixanthogen Chemical compound CCOC(=S)SSC(=S)OCC FVIGODVHAVLZOO-UHFFFAOYSA-N 0.000 description 1
• 101100261976 Drosophila melanogaster trk gene Proteins 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 208000019878 Eales disease Diseases 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 108091008815 Eph receptors Proteins 0.000 description 1
• 102000056118 Ephrin receptor family Human genes 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 206010015866 Extravasation Diseases 0.000 description 1
• 201000004939 Fanconi anemia Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
• 108010029961 Filgrastim Proteins 0.000 description 1
• 108010091820 Focal Adhesion Kinase 2 Proteins 0.000 description 1
• WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
• 102100033840 General transcription factor IIF subunit 1 Human genes 0.000 description 1
• 208000034951 Genetic Translocation Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108010069236 Goserelin Proteins 0.000 description 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 206010066476 Haematological malignancy Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 201000002563 Histoplasmosis Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
• 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
• 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 1
• 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
• 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
• 206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 102000003746 Insulin Receptor Human genes 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 241001248590 Isaria Species 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• 101150009057 JAK2 gene Proteins 0.000 description 1
• 101150069380 JAK3 gene Proteins 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• 206010023330 Keloid scar Diseases 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• UVSVTDVJQAJIFG-VURMDHGXSA-N LFM-A13 Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC(Br)=CC=C1Br UVSVTDVJQAJIFG-VURMDHGXSA-N 0.000 description 1
• UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
• 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
• 206010024612 Lipoma Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 206010025412 Macular dystrophy congenital Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 206010064912 Malignant transformation Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 208000024599 Mooren ulcer Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 1
• 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
• NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
• QSACCXVHEVWNMX-UHFFFAOYSA-N N-acetylanthranilic acid Chemical compound CC(=O)NC1=CC=CC=C1C(O)=O QSACCXVHEVWNMX-UHFFFAOYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 206010051081 Nodular regenerative hyperplasia Diseases 0.000 description 1
• 108010016076 Octreotide Proteins 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 208000001715 Osteoblastoma Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 101150054473 PTK2 gene Proteins 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• 241001111421 Pannus Species 0.000 description 1
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
• 206010033733 Papule Diseases 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• 208000003971 Posterior uveitis Diseases 0.000 description 1
• 208000004210 Pressure Ulcer Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
• 102100026375 Protein PML Human genes 0.000 description 1
• 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
• 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
• 108010021833 Proto-Oncogene Proteins c-yes Proteins 0.000 description 1
• 201000002154 Pterygium Diseases 0.000 description 1
• 101150094745 Ptk2b gene Proteins 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 101100517381 Rattus norvegicus Ntrk1 gene Proteins 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
• 208000007135 Retinal Neovascularization Diseases 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• 108060006706 SRC Proteins 0.000 description 1
• 102000001332 SRC Human genes 0.000 description 1
• 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
• 101100537955 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trk1 gene Proteins 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
• 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
• 241000270295 Serpentes Species 0.000 description 1
• 102100030326 Serpin B4 Human genes 0.000 description 1
• 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 108700025695 Suppressor Genes Proteins 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• 206010043391 Thalassaemia beta Diseases 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• 208000026062 Tissue disease Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 102100021788 Tyrosine-protein kinase Yes Human genes 0.000 description 1
• 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
• 206010064996 Ulcerative keratitis Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
• 206010047663 Vitritis Diseases 0.000 description 1
• 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 1
• 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
• MUAPLWILCIPRQL-UHFFFAOYSA-N [4-[4-[[3-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]carbamoyl]anilino]quinolin-6-yl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1NC1=CC=CC(NC(=O)C=2C=CC(NC=3C4=CC([NH3+])=CC=C4N=CC=3)=CC=2)=C1 MUAPLWILCIPRQL-UHFFFAOYSA-N 0.000 description 1
• XMVZZXLRFCJLDI-UHFFFAOYSA-N [4-[4-[[3-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]carbamoyl]anilino]quinolin-7-yl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1NC1=CC=CC(NC(=O)C=2C=CC(NC=3C4=CC=C([NH3+])C=C4N=CC=3)=CC=2)=C1 XMVZZXLRFCJLDI-UHFFFAOYSA-N 0.000 description 1
• YXHHJKHMJQURDQ-UHFFFAOYSA-N [4-[4-[[4-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]carbamoyl]anilino]quinolin-6-yl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1NC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1NC1=CC=NC2=CC=C([NH3+])C=C12 YXHHJKHMJQURDQ-UHFFFAOYSA-N 0.000 description 1
• MUIPJWOYDRJSLU-UHFFFAOYSA-N [4-[[3-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]carbamoyl]phenyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1NC1=CC=CC(NC(=O)C=2C=CC([NH3+])=CC=2)=C1 MUIPJWOYDRJSLU-UHFFFAOYSA-N 0.000 description 1
• HFCMBQHWIOJEEF-UHFFFAOYSA-N [4-[[4-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]carbamoyl]phenyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1NC(C=C1)=CC=C1NC(=O)C1=CC=C([NH3+])C=C1 HFCMBQHWIOJEEF-UHFFFAOYSA-N 0.000 description 1
• DALLNVJQOKDAPF-UHFFFAOYSA-N [Cl-].[Cl-].C[N+]1=CC=C(C=C1)NC1=CC=C(C=C1)NC(C1=CC=C(C=C1)NC1=CC=NC2=CC(=CC=C12)N)=O.C[N+]1=CC=C(C=C1)NC1=CC=C(C=C1)NC(C1=CC=C(C=C1)NC1=CC=NC2=CC(=CC=C12)N)=O Chemical compound [Cl-].[Cl-].C[N+]1=CC=C(C=C1)NC1=CC=C(C=C1)NC(C1=CC=C(C=C1)NC1=CC=NC2=CC(=CC=C12)N)=O.C[N+]1=CC=C(C=C1)NC1=CC=C(C=C1)NC(C1=CC=C(C=C1)NC1=CC=NC2=CC(=CC=C12)N)=O DALLNVJQOKDAPF-UHFFFAOYSA-N 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• FZEYVTFCMJSGMP-UHFFFAOYSA-N acridone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3NC2=C1 FZEYVTFCMJSGMP-UHFFFAOYSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000002156 adsorbate Substances 0.000 description 1
• 229960001445 alitretinoin Drugs 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• 150000001371 alpha-amino acids Chemical class 0.000 description 1
• 235000008206 alpha-amino acids Nutrition 0.000 description 1
• HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
• 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000000843 anti-fungal effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000000842 anti-protozoal effect Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 210000000436 anus Anatomy 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 208000021328 arterial occlusion Diseases 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
• 229960004853 betadex Drugs 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 208000037512 bile duct cyst Diseases 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• ZCILODAAHLISPY-UHFFFAOYSA-N biphenyl ether Natural products C1=C(CC=C)C(O)=CC(OC=2C(=CC(CC=C)=CC=2)O)=C1 ZCILODAAHLISPY-UHFFFAOYSA-N 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 229940045348 brown mixture Drugs 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 230000035563 calcemia Effects 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 229940112129 campath Drugs 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• 229940022399 cancer vaccine Drugs 0.000 description 1
• 238000009566 cancer vaccine Methods 0.000 description 1
• RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• NMMGUHANGUWNBN-OGLOGDKOSA-N cep-751 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1C[C@](OC)(CO)[C@]4(C)O1 NMMGUHANGUWNBN-OGLOGDKOSA-N 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• 201000001173 choledochal cyst Diseases 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 231100000005 chromosome aberration Toxicity 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 101150014604 cpg-3 gene Proteins 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• 229940109275 cyclamate Drugs 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
• 208000024389 cytopenia Diseases 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229940059359 dacogen Drugs 0.000 description 1
• 230000006196 deacetylation Effects 0.000 description 1
• 238000003381 deacetylation reaction Methods 0.000 description 1
• 230000008260 defense mechanism Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 239000012649 demethylating agent Substances 0.000 description 1
• 230000017858 demethylation Effects 0.000 description 1
• 238000010520 demethylation reaction Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• ZZTURJAZCMUWEP-UHFFFAOYSA-N diaminomethylideneazanium;hydrogen sulfate Chemical compound NC(N)=N.OS(O)(=O)=O ZZTURJAZCMUWEP-UHFFFAOYSA-N 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• QPMCZYBKIGHJPV-UHFFFAOYSA-N dimethyl-[4-[4-[[4-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]carbamoyl]anilino]quinolin-6-yl]azanium;dichloride Chemical compound [Cl-].[Cl-].C12=CC([NH+](C)C)=CC=C2N=CC=C1NC(C=C1)=CC=C1C(=O)NC(C=C1)=CC=C1NC1=CC=[N+](C)C=C1 QPMCZYBKIGHJPV-UHFFFAOYSA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 150000002066 eicosanoids Chemical class 0.000 description 1
• 238000000921 elemental analysis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000029578 entry into host Effects 0.000 description 1
• 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 208000010932 epithelial neoplasm Diseases 0.000 description 1
• 239000003687 estradiol congener Substances 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• WEHDKOIKSRMLEK-UHFFFAOYSA-N ethanesulfonic acid;2-hydroxyethanesulfonic acid Chemical compound CCS(O)(=O)=O.OCCS(O)(=O)=O WEHDKOIKSRMLEK-UHFFFAOYSA-N 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 238000004299 exfoliation Methods 0.000 description 1
• 230000036251 extravasation Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 206010016629 fibroma Diseases 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 229960004177 filgrastim Drugs 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
• 229960000556 fingolimod Drugs 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 239000008098 formaldehyde solution Substances 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
• 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
• 201000008361 ganglioneuroma Diseases 0.000 description 1
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 229940080856 gleevec Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 229960004275 glycolic acid Drugs 0.000 description 1
• 229960003690 goserelin acetate Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 208000010758 granulomatous inflammation Diseases 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 231100000226 haematotoxicity Toxicity 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 210000002768 hair cell Anatomy 0.000 description 1
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
• 208000013653 hyalitis Diseases 0.000 description 1
• 229960002474 hydralazine Drugs 0.000 description 1
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 201000004933 in situ carcinoma Diseases 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 238000012739 integrated shape imaging system Methods 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• 229940084651 iressa Drugs 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 229960004125 ketoconazole Drugs 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• YPJRHEKCFKOVRT-UHFFFAOYSA-N lerociclib Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 YPJRHEKCFKOVRT-UHFFFAOYSA-N 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 229960001614 levamisole Drugs 0.000 description 1
• 230000002197 limbic effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 229910003002 lithium salt Inorganic materials 0.000 description 1
• 159000000002 lithium salts Chemical class 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 235000021266 loss of appetite Nutrition 0.000 description 1
• 208000019017 loss of appetite Diseases 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 229940098895 maleic acid Drugs 0.000 description 1
• 230000036212 malign transformation Effects 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
• 229960003248 mifepristone Drugs 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 230000021332 multicellular organism growth Effects 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 208000001491 myopia Diseases 0.000 description 1
• 230000004379 myopia Effects 0.000 description 1
• 208000009091 myxoma Diseases 0.000 description 1
• RIXIAEQTZNQBKF-UHFFFAOYSA-N n-(3-nitrophenyl)pyridin-4-amine Chemical compound [O-][N+](=O)C1=CC=CC(NC=2C=CN=CC=2)=C1 RIXIAEQTZNQBKF-UHFFFAOYSA-N 0.000 description 1
• VNPCQOHDHBCPKS-UHFFFAOYSA-N n-(4-aminophenyl)-3-[(1-methylpyridin-1-ium-4-yl)amino]benzamide;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1NC1=CC=CC(C(=O)NC=2C=CC(N)=CC=2)=C1 VNPCQOHDHBCPKS-UHFFFAOYSA-N 0.000 description 1
• FIUIWMNASJNWRE-UHFFFAOYSA-N n-(4-aminophenyl)-3-[(2,6-diaminopyrimidin-4-yl)amino]benzamide;hydrochloride Chemical compound Cl.C1=CC(N)=CC=C1NC(=O)C1=CC=CC(NC=2N=C(N)N=C(N)C=2)=C1 FIUIWMNASJNWRE-UHFFFAOYSA-N 0.000 description 1
• HZZXGBJDMLFOPH-UHFFFAOYSA-N n-(4-aminophenyl)-4-[(1-methylpyridin-1-ium-4-yl)amino]benzamide;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1NC1=CC=C(C(=O)NC=2C=CC(N)=CC=2)C=C1 HZZXGBJDMLFOPH-UHFFFAOYSA-N 0.000 description 1
• BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
• DMYVFGDHFBXYFJ-UHFFFAOYSA-N n-[3-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]-4-[(6-nitroquinolin-4-yl)amino]benzamide;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1NC1=CC=CC(NC(=O)C=2C=CC(NC=3C4=CC(=CC=C4N=CC=3)[N+]([O-])=O)=CC=2)=C1 DMYVFGDHFBXYFJ-UHFFFAOYSA-N 0.000 description 1
• MOTUWWONBCVBJS-UHFFFAOYSA-N n-[3-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]-4-[(7-nitroquinolin-4-yl)amino]benzamide;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1NC1=CC=CC(NC(=O)C=2C=CC(NC=3C4=CC=C(C=C4N=CC=3)[N+]([O-])=O)=CC=2)=C1 MOTUWWONBCVBJS-UHFFFAOYSA-N 0.000 description 1
• URJMMWRXMSWMHJ-UHFFFAOYSA-N n-[3-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]-4-nitrobenzamide Chemical compound NC1=NC(C)=CC(NC=2C=C(NC(=O)C=3C=CC(=CC=3)[N+]([O-])=O)C=CC=2)=N1 URJMMWRXMSWMHJ-UHFFFAOYSA-N 0.000 description 1
• RMJPVRWBBVLSGT-QOFFZXOYSA-N n-[3-[(e)-n-(diaminomethylideneamino)-c-methylcarbonimidoyl]phenyl]-4-nitrobenzamide;dihydrochloride Chemical compound Cl.Cl.NC(N)=N\N=C(/C)C1=CC=CC(NC(=O)C=2C=CC(=CC=2)[N+]([O-])=O)=C1 RMJPVRWBBVLSGT-QOFFZXOYSA-N 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• GUXKKHINPPQDDI-UHFFFAOYSA-N n-[4-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]-4-(quinolin-4-ylamino)benzamide;chloride;hydrochloride Chemical compound Cl.[Cl-].C1=C[N+](C)=CC=C1NC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1NC1=CC=NC2=CC=CC=C12 GUXKKHINPPQDDI-UHFFFAOYSA-N 0.000 description 1
• DNENJUZFGFCLLM-UHFFFAOYSA-N n-[4-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]-4-[(6-nitroquinolin-4-yl)amino]benzamide;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1NC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1NC1=CC=NC2=CC=C([N+]([O-])=O)C=C12 DNENJUZFGFCLLM-UHFFFAOYSA-N 0.000 description 1
• RTCKTLPVEATMFA-UHFFFAOYSA-N n-[4-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]-4-[(6-nitroquinolin-4-yl)amino]benzamide;chloride;hydrochloride Chemical compound Cl.[Cl-].C1=C[N+](C)=CC=C1NC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1NC1=CC=NC2=CC=C([N+]([O-])=O)C=C12 RTCKTLPVEATMFA-UHFFFAOYSA-N 0.000 description 1
• ZOJKSGOOIXEXLQ-UHFFFAOYSA-N n-[4-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]-4-[(7-nitroquinolin-4-yl)amino]benzamide;dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1NC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1NC1=CC=NC2=CC([N+]([O-])=O)=CC=C12.C1=C[N+](C)=CC=C1NC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1NC1=CC=NC2=CC([N+]([O-])=O)=CC=C12 ZOJKSGOOIXEXLQ-UHFFFAOYSA-N 0.000 description 1
• UPJOBVRMKCRVAF-UHFFFAOYSA-N n-[4-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]-4-[[6-(dimethylamino)quinolin-4-yl]amino]benzamide;hydrochloride Chemical compound Cl.C12=CC(N(C)C)=CC=C2N=CC=C1NC(C=C1)=CC=C1C(=O)NC(C=C1)=CC=C1NC1=CC(C)=NC(N)=N1 UPJOBVRMKCRVAF-UHFFFAOYSA-N 0.000 description 1
• YKNPOUALBBQBLJ-UHFFFAOYSA-N n-[4-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]-4-[[7-(dimethylamino)quinolin-4-yl]amino]benzamide;hydrochloride Chemical compound Cl.C=1C=NC2=CC(N(C)C)=CC=C2C=1NC(C=C1)=CC=C1C(=O)NC(C=C1)=CC=C1NC1=CC(C)=NC(N)=N1 YKNPOUALBBQBLJ-UHFFFAOYSA-N 0.000 description 1
• PXUMMBNGIKYCSQ-UHFFFAOYSA-N n-[4-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]-4-nitrobenzamide Chemical compound NC1=NC(C)=CC(NC=2C=CC(NC(=O)C=3C=CC(=CC=3)[N+]([O-])=O)=CC=2)=N1 PXUMMBNGIKYCSQ-UHFFFAOYSA-N 0.000 description 1
• VBOXXZQBMYJPTP-UHFFFAOYSA-N n-[4-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]-5-(quinolin-4-ylamino)pyridine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.NC1=NC(C)=CC(NC=2C=CC(NC(=O)C=3N=CC(NC=4C5=CC=CC=C5N=CC=4)=CC=3)=CC=2)=N1 VBOXXZQBMYJPTP-UHFFFAOYSA-N 0.000 description 1
• CKCDHDKRDNJULK-UHFFFAOYSA-N n-[4-[(6-aminoquinolin-1-ium-4-yl)amino]phenyl]acetamide;chloride Chemical compound [Cl-].C1=CC(NC(=O)C)=CC=C1NC1=CC=[NH+]C2=CC=C(N)C=C12 CKCDHDKRDNJULK-UHFFFAOYSA-N 0.000 description 1
• WCFLONMIHCSKSO-UHFFFAOYSA-N n-[4-[(6-nitroquinolin-1-ium-4-yl)amino]phenyl]acetamide;chloride Chemical compound [Cl-].C1=CC(NC(=O)C)=CC=C1NC1=CC=[NH+]C2=CC=C([N+]([O-])=O)C=C12 WCFLONMIHCSKSO-UHFFFAOYSA-N 0.000 description 1
• QBSGDPWPGWCQMF-UHFFFAOYSA-N n-[4-[(7-aminoquinolin-4-yl)amino]phenyl]-4-[(1-methylpyridin-1-ium-4-yl)amino]benzamide;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1NC1=CC=C(C(=O)NC=2C=CC(NC=3C4=CC=C(N)C=C4N=CC=3)=CC=2)C=C1 QBSGDPWPGWCQMF-UHFFFAOYSA-N 0.000 description 1
• DRLFIICWDSAPMX-XZISABOOSA-N n-[4-[(e)-n-(diaminomethylideneamino)-c-methylcarbonimidoyl]phenyl]-4-nitrobenzamide;hydrochloride Chemical compound Cl.C1=CC(C(=N/N=C(N)N)/C)=CC=C1NC(=O)C1=CC=C([N+]([O-])=O)C=C1 DRLFIICWDSAPMX-XZISABOOSA-N 0.000 description 1
• JXTCDUIVNINJOD-UHFFFAOYSA-N n-[4-[[6-(dimethylamino)quinolin-4-yl]amino]phenyl]acetamide Chemical compound C12=CC(N(C)C)=CC=C2N=CC=C1NC1=CC=C(NC(C)=O)C=C1 JXTCDUIVNINJOD-UHFFFAOYSA-N 0.000 description 1
• JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• 229960002653 nilutamide Drugs 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 229960002700 octreotide Drugs 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 239000003973 paint Substances 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 150000003905 phosphatidylinositols Chemical group 0.000 description 1
• 150000003009 phosphonic acids Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 150000003014 phosphoric acid esters Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 1
• 150000003058 platinum compounds Chemical class 0.000 description 1
• 210000001778 pluripotent stem cell Anatomy 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
• 229960000244 procainamide Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
• 229940095574 propionic acid Drugs 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 208000028172 protozoa infectious disease Diseases 0.000 description 1
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
• 150000007660 quinolones Chemical class 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 102000009929 raf Kinases Human genes 0.000 description 1
• 108010077182 raf Kinases Proteins 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 230000007420 reactivation Effects 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 239000011369 resultant mixture Substances 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 102000003702 retinoic acid receptors Human genes 0.000 description 1
• 108090000064 retinoic acid receptors Proteins 0.000 description 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
• 229960002530 sargramostim Drugs 0.000 description 1
• 108010038379 sargramostim Proteins 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 208000011581 secondary neoplasm Diseases 0.000 description 1
• 230000008684 selective degradation Effects 0.000 description 1
• 201000006476 shipyard eye Diseases 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 201000008261 skin carcinoma Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 208000010485 smooth muscle tumor Diseases 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 159000000000 sodium salts Chemical group 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000012265 solid product Substances 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000759 toxicological effect Toxicity 0.000 description 1
• 206010044325 trachoma Diseases 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 108010014677 transcription factor TFIIE Proteins 0.000 description 1
• 108010014678 transcription factor TFIIF Proteins 0.000 description 1
• 230000037426 transcriptional repression Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
• 102000047459 trkC Receptor Human genes 0.000 description 1
• 108010064892 trkC Receptor Proteins 0.000 description 1
• 239000000225 tumor suppressor protein Substances 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
• TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 1
• 230000036269 ulceration Effects 0.000 description 1
• 229960001055 uracil mustard Drugs 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 231100000925 very toxic Toxicity 0.000 description 1
• 229940065658 vidaza Drugs 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 229950005839 vinzolidine Drugs 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1